文献速递肿瘤 PET/CT核素与放射性配体治疗

位点特异性偶联的单域抗体通过免疫PET成功识别表达磷脂酰肌醇蛋白聚糖-3的肝癌

Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
PubMed 文献 · J Nucl Med · 2023-03-30

研究比较了传统赖氨酸导向偶联与分选酶介导的位点特异性偶联方法制备的GPC3特异性人单域抗体HN3的89Zr标记PET探针。在多种小鼠移植瘤模型中,位点特异性探针89Zr-ssHN3较传统探针89Zr-nHN3具有更高的肿瘤摄取和更低的肝脏蓄积,肿瘤/肝脏信号比更优,且与18F-FDG相比肿瘤蓄积更一致。结果表明基于HN3的单域抗体探针有望用于GPC3靶向的肝癌PET成像。

要点

  • 89Zr-ssHN3与89Zr-nHN3在体外对GPC3均显示纳摩尔级亲和力。
  • 89Zr-ssHN3较89Zr-nHN3具有更优的生物分布和药代动力学,包括更高的肿瘤摄取和更低的肝脏蓄积。
  • 89Zr-ssHN3在移植瘤模型中肿瘤/肝脏信号比优于89Zr-nHN3。

核心结论

  • 在移植瘤模型中,89Zr-ssHN3在肿瘤摄取和肿瘤/肝脏信号比方面较传统修饰的89Zr-nHN3显示出明显优势。
  • 基于HN3的单域抗体探针具有用于GPC3靶向肝癌PET成像的潜力。

研究设计与样本

  • 研究使用传统偶联和基于分选酶的位点特异性偶联方法,分别制备GPC3特异性人单域抗体HN3的PET探针:天然HN3(nHN3)-DFO和位点特异性修饰HN3(ssHN3)-DFO。
  • 两种偶联物均用89Zr标记,并在体外测定结合亲和力,在体内评估对GPC3阳性肿瘤的靶向结合。
  • 体内研究使用荷有同源A431和A431-GPC3+移植瘤以及HepG2肝癌移植瘤的小鼠进行生物分布和PET/CT图像分析。

主要发现

  • 89Zr-ssHN3和89Zr-nHN3在体外对GPC3均显示纳摩尔级亲和力。
  • 在荷有同源A431和A431-GPC3+移植瘤以及HepG2肝癌移植瘤的小鼠中,生物分布和PET/CT图像分析显示两种偶联物均能特异性识别GPC3阳性肿瘤。
  • 89Zr-ssHN3表现出更有利的生物分布和药代动力学特性,包括更高的肿瘤摄取和更低的肝脏蓄积。
  • 对同一批小鼠分别用18F-FDG和89Zr-ssHN3进行对比PET/CT研究,显示单域抗体偶联物的肿瘤蓄积更一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary liver cancer is the third leading cause of cancer-related deaths, and its incidence and mortality are increasing worldwide. Hepatocellular carcinoma (HCC) accounts for 80% of primary liver cancer cases. Glypican-3 (GPC3) is a heparan sulfate proteoglycan that histopathologically defines HCC and represents an attractive tumor-selective marker for radiopharmaceutical imaging and therapy for this disease. Single-domain antibodies are a promising scaffold for imaging because of their favorable pharmacokinetic properties, good tumor penetration, and renal clearance. Although conventional lysine-directed bioconjugation can be used to yield conjugates for radiolabeling full-length antibodies, this stochastic approach risks negatively affecting target binding of the smaller single-domain antibodies. To address this challenge, site-specific approaches have been explored. Here, we used conventional and sortase-based site-specific conjugation methods to engineer GPC3-specific human single-domain antibody (HN3) PET probes. Methods: Bifunctional deferoxamine (DFO) isothiocyanate was used to synthesize native HN3 (nHN3)-DFO. Site-specifically modified HN3 (ssHN3)-DFO was engineered using sortase-mediated conjugation of triglycine-DFO chelator and HN3 containing an LPETG C-terminal tag. Both conjugates were radiolabeled with 89Zr, and their binding affinity in vitro and target engagement of GPC3-positive (GPC3+) tumors in vivo were determined. Results: Both 89Zr-ssHN3 and 89Zr-nHN3 displayed nanomolar affinity for GPC3 in vitro. Biodistribution and PET/CT image analysis in mice bearing isogenic A431 and A431-GPC3+ xenografts, as well as in HepG2 liver cancer xenografts, showed that both conjugates specifically identify GPC3+ tumors. 89Zr-ssHN3 exhibited more favorable biodistribution and pharmacokinetic properties, including higher tumor uptake and lower liver accumulation. Comparative PET/CT studies on mice imaged with both 18F-FDG and 89Zr-ssHN3 showed more consistent tumor accumulation for the single-domain antibody conjugate, further establishing its potential for PET imaging. Conclusion: 89Zr-ssHN3 showed clear advantages in tumor uptake and tumor-to-liver signal ratio over the conventionally modified 89Zr-nHN3 in xenograft models. Our results establish the potential of HN3-based single-domain antibody probes for GPC3-directed PET imaging of liver cancers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fayn S, King AP, Gutsche NT, et al. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET. J Nucl Med. 2023. PMID: 36997331. doi:10.2967/jnumed.122.265171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。